AMGN Live signals | Maximize Profits with Getagraph.com

SELL 910 min ago

@ $300.57

Issued: 7 May 2024 @ 15:42

Return: -0.09%

Previous signal: May 7 - 11:59

Previous signal: Buy

Return: -0.20 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 16:00):

Stats
Today's Volume	2.44M
Average Volume	2.92M
Market Cap	160.94B
EPS	$0 ( 2024-05-02 )
Next earnings date	( $4.87 ) 2024-08-01
Last Dividend	$2.25 ( 2024-02-15 )
Next Dividend	$0 ( N/A )
P/E	42.84
ATR14	$4.40 (1.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-05	Santos Esteban	Sell	617	Common Stock
2024-05-05	Reese David M	Sell	633	Common Stock
2024-05-05	Miller Derek	Sell	78	Common Stock
2024-05-05	Khosla Rachna	Sell	41	Common Stock
2024-05-05	Grygiel Nancy A.	Sell	82	Common Stock

INSIDER POWER
14.33
Last 98 transactions
Buy: 140 621 \| Sell: 110 561

Volume Correlation

Long: 0.87 (strong)

Short: -0.88 (strong negative)

Signal:(48) Neutral

Amgen Inc Correlation

10 Most Positive Correlations
SMIT	0.929
CNCE	0.926
PLIN	0.925
RETA	0.921
CTIC	0.921
LAWS	0.921
PIII	0.917
IMTX	0.914
OP	0.913
OBT	0.912

10 Most Negative Correlations
RGLD	-0.945
GRFS	-0.941
IMVT	-0.939
RMRM	-0.937
WB	-0.936
HCM	-0.934
HERA	-0.934
HOFT	-0.933
SOCL	-0.933
IPKW	-0.93

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amgen Inc Correlation - Currency/Commodity

0.33
( neutral )

-0.19
( neutral )

-0.76
( moderate negative )

0.13
( neutral )

0.31
( neutral )

0.74
( moderate )

Amgen Inc Financials

Annual	2023
Revenue:	$28.19B
Gross Profit:	$19.74B (70.02 %)
EPS:	$12.56

FY	2023
Revenue:	$28.19B
Gross Profit:	$19.74B (70.02 %)
EPS:	$12.56

FY	2022
Revenue:	$26.32B
Gross Profit:	$19.92B (75.66 %)
EPS:	$12.18

FY	2021
Revenue:	$25.98B
Gross Profit:	$19.53B (75.16 %)
EPS:	$10.06

Financial Reports:

No articles found.

Amgen Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.940 (N/A)	$1.940 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.13 (N/A)	$2.25 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Amgen Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.90 - Stable (37.94%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.280	2011-08-16
Last Dividend	$2.25	2024-02-15
Next Dividend	$0	N/A
Payout Date	2024-03-07
Next Payout Date	N/A
# dividends	51	--
Total Paid Out	$61.13	--
Avg. Dividend % Per Year	2.40%	--
Score	5.57	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.90
Div. Directional Score	8.68	--

Next Divdend (Est)
(2024-07-01)

$2.30 Estimate 61.99 %

Dividend Stability

0.99 Excellent

Dividend Score

5.57

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0.560	1.01%
2012	$1.440	2.25%
2013	$1.880	2.11%
2014	$2.44	2.11%
2015	$3.16	1.98%
2016	$4.00	2.53%
2017	$4.60	3.05%
2018	$5.28	2.98%
2019	$5.80	3.02%
2020	$6.40	2.67%
2021	$7.04	3.11%
2022	$7.76	3.42%
2023	$8.52	3.26%
2024	$2.25	0.76%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.128	1.500	7.45	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0405	1.200	8.65	10.00	[0 - 0.3]
returnOnEquityTTM	0.586	1.500	4.60	6.90	[0.1 - 1]
payoutRatioTTM	1.230	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.422	0.800	7.89	6.31	[1 - 3]
quickRatioTTM	0.836	0.800	9.79	7.83	[0.8 - 2.5]
cashRatioTTM	0.492	1.500	8.38	10.00	[0.2 - 2]
debtRatioTTM	0.689	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	2.19	1.000	-0.299	-0.299	[3 - 30]
operatingCashFlowPerShareTTM	15.10	2.00	4.97	9.93	[0 - 30]
freeCashFlowPerShareTTM	13.24	2.00	3.38	6.76	[0 - 20]
debtEquityRatioTTM	12.75	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.663	1.000	2.28	2.28	[0.2 - 0.8]
operatingProfitMarginTTM	0.235	1.000	7.31	7.31	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.126	1.000	-0.409	-0.409	[0.2 - 2]
assetTurnoverTTM	0.317	0.800	-1.220	-0.976	[0.5 - 2]
Total Score				10.46

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	42.77	1.000	5.78	0	[1 - 100]
returnOnEquityTTM	0.586	2.50	6.53	6.90	[0.1 - 1.5]
freeCashFlowPerShareTTM	13.24	2.00	5.59	6.76	[0 - 30]
dividendYielPercentageTTM	2.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	15.10	2.00	4.97	9.93	[0 - 30]
payoutRatioTTM	1.230	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	1.238	1.500	5.08	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.275	1.000	5.63	0	[0.1 - 0.5]
Total Score				6.90

Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.